All In Biotech

NDA 208264 · Adienne SA

Tepadina and Sodium Chloride

Thiotepa · Intravenous, Intracavitary, Intravenous, Intravesical · Alkylating Drug

Orphan

Last checked: Nov 19, 2026Latest source record: Jan 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Jan 26, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

324

39 Phase 3, 55 recruiting

FAERS reports

9,762

9,540 serious, 2,735 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SEVERE MYELOSUPPRESSION and CARCINOGENICITY TEPADINA may cause severe marrow suppression, and high doses may cause marrow ablation with resulting infection or bleeding. Monitor hematologic laboratory parameters. Hematopoietic progenitor (stem) cell transplantation (HSCT) is required to prevent potentially fatal complications of the prolonged myelosuppression after high doses of TEPADINA [see Warnings and Precautions (5.1) ] TEPADINA should be considered potentially carcinogenic in humans [see Warnings and Precautions (5.7) ] WARNING: SEVERE MYELOSUPPRESSION and CARCINOGENICITY See full prescribing information for complete boxed warning. May cause severe marrow suppression or ablation with resulting infection or bleeding. Monitor hematologic laboratory parameters. (5.1) Potentially carcinogenic in humans. (5.7)

What it is approved for

From the label in effect Jan 30, 2026.

TEPADINA (thiotepa) is an alkylating drug indicated: To reduce the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia. (1.1 , 14) For treatment of adenocarcinoma of the breast or ovary. (1.2) For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. (1.3) For treatment of superficial papillary carcinoma of the urinary bladder. (1.4) 1.1 Class 3 Beta-Thalassemia TEPADINA is indicated to reduce the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia [see Clinical Studies ( 14 ) ] . 1.2 Adenocarcinoma of the Breast or Ovary TEPADINA is indicated for treatment of adenocarcinoma of the breast or ovary. 1.3 Malignant Effusions TEPADINA is indicated for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. 1.4 Superficial Papillary Carcinoma of the Urinary Bladder TEPADINA is indicated for treatment of superficial papillary carcinoma of the urinary bladder. 1.1 Class 3 Beta-Thalassemia TEPADINA is indicated to reduce the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia [see Clinical Studies ( 14 ) ] . 1.2 Adenocarcinoma of the Breast or Ovary TEPADINA is indicated for...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 26, 2017 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLabelLetterReview
4 products under this application
  • TEPADINA AND SODIUM CHLORIDE · THIOTEPA 200MG · POWDER, INTRAVENOUS · Prescription
  • TEPADINA · THIOTEPA 15MG/VIAL · POWDER, INTRACAVITARY, INTRAVENOUS, INTRAVESICAL · Prescription · TE AP
  • TEPADINA AND SODIUM CHLORIDE · THIOTEPA 400MG · POWDER, INTRAVENOUS · Prescription
  • TEPADINA · THIOTEPA 100MG/VIAL · POWDER, INTRACAVITARY, INTRAVENOUS, INTRAVESICAL · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Thiotepa" as an intervention, any sponsor and status, largest first.

All 324 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,227
  • febrile neutropenia853
  • mucosal inflammation830
  • product use in unapproved indication601
  • drug ineffective558
  • pyrexia533
  • cytomegalovirus infection531
  • acute graft versus host disease465
  • acute graft versus host disease in skin464
  • cytomegalovirus infection reactivation454
  • infection435
  • neutropenia422

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200449
200538
200644
200736
200878
2009108
2010159
2011158
2012120
201388
2014267
2015125
2016221
2017511
2018853
2019853
2020997
2021831
2022672
2023584
2024981
20251,209
2026780

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 527 on PubMed

Sponsor: Adienne SA · Also marketed as Tepadina

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.